Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 4:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: "pulmonary hypertension" Condition: Hypertension Clear all
Terminated Phase 2 Interventional

A Study of RVT-1201 in Patients With Pulmonary Arterial Hypertension (ELEVATE 1)

NCT03924154
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
RVT-1201, Placebo
Drug
Lead sponsor
Altavant Sciences GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
20
States / cities
Phoenix, Arizona • Sacramento, California • Santa Barbara, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2020 · Synced Jul 24, 2026, 4:58 PM EDT
Completed Phase 2 Interventional Results available

Effect of iNO on Invasively Derived Pulmonary Pressures in Patients With PAH

NCT02734953
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Nitric Oxide
Drug
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 23, 2018 · Synced Jul 24, 2026, 4:58 PM EDT
Terminated Phase 2 Interventional

Tezosentan in Patients With Pulmonary Arterial Hypertension

NCT01094067
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
ACT-050089, Placebo
Drug · Other
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2018 · Synced Jul 24, 2026, 4:58 PM EDT
Completed Phase 3 Interventional Results available

Ranolazine and Pulmonary Hypertension

NCT01174173
View directory record Official record
Conditions
Angina, Pulmonary Arterial Hypertension
Interventions
Ranolazine
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Jul 24, 2026, 4:58 PM EDT
Completed Not applicable Interventional Results available

Auto-PAP for Pulmonary Hypertension Treatment in Decompensated HF Patients With Sleep Apnea.

NCT02963597
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Hypertension, Pulmonary, Heart Failure
Interventions
AirSense™ 10 AutoSet, Standard Medical Therapy
Device · Other
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2020 · Synced Jul 24, 2026, 4:58 PM EDT
Completed Not applicable Interventional

NO Need to Ventilate: A Trial of Non-invasive Inhaled Nitric Oxide in Persistent Pulmonary Hypertension of the Newborn

NCT00139217
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
iNO, Non-invasive nitric oxide
Drug · Procedure
Lead sponsor
Emory University
Other
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 28, 2014 · Synced Jul 24, 2026, 4:58 PM EDT
Not listed Phase 2 Interventional

A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis

NCT05747508
View directory record Official record
Conditions
Pulmonary Fibrosis, Pulmonary Hypertension
Interventions
INOpulse®, Placebo, Long Term Follow Up
Combination Product
Lead sponsor
Bellerophon
Industry
Eligibility
18 Years to 85 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Jul 24, 2026, 4:58 PM EDT
Completed Phase 2 Interventional

Combined Treatment of Resistant Hypertension and Atrial Fibrillation

NCT01117025
View directory record Official record
Conditions
Hypertension, Resistant to Conventional Therapy, Atrial Fibrillation
Interventions
Circumferential PV isolation, Circumferential PVI+renal denervation
Procedure
Lead sponsor
Meshalkin Research Institute of Pathology of Circulation
Network
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Jul 24, 2026, 4:58 PM EDT
Active, not recruiting Phase 2 Interventional

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)

NCT06925750
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Sotatercept, Background PAH Therapy
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Aurora, Colorado • Kansas City, Kansas • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Jul 24, 2026, 4:58 PM EDT
Completed Not applicable Interventional Results available

Piloting Mindfulness Meditation Program for Underserved Racial Minority Adults With Pulmonary Hypertension

NCT05387889
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Mindfulness Meditation for Pulmonary Hypertension (MMPH)
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Jul 24, 2026, 4:58 PM EDT
Recruiting Not applicable Interventional

Mobile Health Intervention to Improve Exercise in Pediatric PH

NCT06549452
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
mHealth Intervention, Usual Care
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
10 Years to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jul 24, 2026, 4:58 PM EDT
Terminated Phase 2 Interventional Results available

Riociguat in Patients With Operable CTEPH Prior to Pulmonary Endarterectomy (PEA Bridging Study)

NCT03273257
View directory record Official record
Conditions
Chronic Thromboembolic Pulmonary Hypertension, CTEPH
Interventions
Riociguat, Placebo, Pulmonary endarterectomy
Drug · Procedure
Lead sponsor
International CTEPH Association
Other
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Jul 24, 2026, 4:58 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

NCT07481981
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil Palmitil Inhalation Powder, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Santa Barbara, California • Anderson, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jul 24, 2026, 4:58 PM EDT
Not yet recruiting Phase 2 Interventional

Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease

NCT07473700
View directory record Official record
Conditions
Hypertension, Pulmonary, Lung Diseases, Interstitial
Interventions
TX000045
Drug
Lead sponsor
Tectonic Operating Company, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Jul 24, 2026, 4:58 PM EDT
Completed No phase listed Observational

sFlt-1:PlGF Ratio in Diagnosing Superimposed Preeclampsia

NCT03441711
View directory record Official record
Conditions
Preeclampsia
Interventions
Not listed
Lead sponsor
University of Tennessee
Other
Eligibility
14 Years to 45 Years · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Jul 24, 2026, 4:58 PM EDT
Completed Not applicable Interventional Results available

The CHIPS Trial (Control of Hypertension In Pregnancy Study)

NCT01192412
View directory record Official record
Conditions
Gestational Hypertension
Interventions
Intervention is blood pressure management approach.
Procedure
Lead sponsor
University of British Columbia
Other
Eligibility
Female only
Enrollment
987 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
11
States / cities
New Haven, Connecticut • Louisville, Kentucky • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Jul 24, 2026, 4:58 PM EDT
Terminated Phase 2 Interventional Results available

Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants

NCT05764265
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
LTP001
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Jul 24, 2026, 4:58 PM EDT
Completed No phase listed Observational

Contrast Enhanced PA Pressure Measurements

NCT06240871
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Pulmonary artery pressure measurements
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 4, 2024 · Synced Jul 24, 2026, 4:58 PM EDT
Completed No phase listed Observational

Pulmonary Perfusion Heterogeneity in Patients With CTEPH Using Functional PET Imaging

NCT02114047
View directory record Official record
Conditions
Chronic Thromboembolic Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Jul 24, 2026, 4:58 PM EDT
Not listed Not applicable Interventional

The Prospective Risk Factor Evaluation & Discovery In CTEPH Study

NCT03470207
View directory record Official record
Conditions
Chronic Thromboembolic Pulmonary Hypertension
Interventions
Post-pulmonary embolism follow up protocol
Procedure
Lead sponsor
Mark W. Dodson
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Jul 24, 2026, 4:58 PM EDT
Completed Phase 2 Interventional Results available

11C-acetate/18Fluorodeoxyglucose-FDG PET/CT and Cardiac MRI in Pulmonary Hypertension

NCT01917136
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
11C-acetate, [18F]Fluoro-2-deoxy-2-D-glucose, Cardiac MRI
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Jul 24, 2026, 4:58 PM EDT
Completed Phase 3 Interventional

Renal Artery Denervation In Addition to Catheter Ablation To Eliminate Atrial Fibrillation

NCT01873352
View directory record Official record
Conditions
Atrial Fibrillation, Hypertension
Interventions
catheter ablation, renal sympathetic denervation
Procedure
Lead sponsor
Meshalkin Research Institute of Pathology of Circulation
Network
Eligibility
18 Years to 75 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Short Hills, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Jul 24, 2026, 4:58 PM EDT
Completed Phase 4 Interventional Results available

Targeting Right Ventricle in Pulmonary Hypertension Gilead

NCT02829034
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Jul 24, 2026, 4:58 PM EDT